Article Information
History
- April 28, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Laura A Sena1,†,*,
- Rajendra Kumar1,†,
- David E Sanin1,
- Elizabeth A Thompson1,
- D Marc Rosen1,
- Susan L Dalrymple1,
- Lizamma Antony1,
- Yuhan Yang1,
- Carolina Gomes-Alexandre1,
- Jessica L Hicks1,
- Tracy Jones1,
- Kiara A. Bowers1,
- Jillian N Eskra1,
- Jennifer Meyers1,
- Anuj Gupta1,
- Alyza Skaist1,
- Srinivasan Yegnasubramanian1,
- Jun Luo1,
- W Nathaniel Brennen1,
- Sushant K Kachhap1,
- Emmanuel S Antonarakis1,2,
- Angelo M De Marzo1,
- John T Isaacs1,
- Mark C Markowski1,‡ and
- Samuel R Denmeade1,‡,*
- 1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
- 2University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA
- ↵*Corresponding authors’ emails: laura.sena{at}jhmi.edu and denmesa{at}jhmi.edu
Posted April 28, 2022.
Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy
